Calculated age based on Date of Birth and Date of Visit




Assisted ventilation required
Recurrent respiratory tract infection
Facial weakness
Bulbar weakness
Respiratory weakness






Neck weakness
Tongue wasting
Muscle wasting
EMG result

myopathic
neurogenic
Repetitive nerve stimulation result


Exacerbation with infection






























Episodic apnoea












Apneic episodes in last 12 months


Myasthenic crisis in last 12 months


























































































Pseudonym
Initial diagnosis
Patient status
Date of Death
Cause of death
Cause
inst
External Institute
External Institute
Contact consent
Year of birth
Date of diagnosis
Age at diagnosis
Weight
Height
BMI
Sex
Ethnicity
Other ethnicity
Alcohol
Smoking
is_smoker
Smoking amount
First degree relative with autoimmune liver disease
Type of autoimmune liver disease?
Full simplified AIH score available
Simplified AIH score
Liver biopsy
Date of liver biopsy
Desmet and Scheuer classification assessed
Fibrosis stage (Desmet and Scheuer)
Grade (Scheuer)
Ishak score assessed
Fibrosis stage (Ishak)
mHAI
Additional signs of NAFLD?
Additional signs of NASH?
Immunosuppression at biopsy (if more than 7 days)
Transient elastography (FibroScan)
Liver stiffness (FibroScan)
Interquartile range (IQR)
Spleen size (diameter)
Cholangiography (MRCP or ERCP)
IBD
Type of IBD
Tanner stage (1-5 for male genital or female breast)
Tanner stage (1-5 pubic hair)
Liver-related complications or signs of cirrhosis
Liver imaging consistent with cirrhosis
Ascites
Esophageal or gastric varices
Variceal bleeding
Overt encephalopathy
Hepatorenal syndrome
AST
ALT
Total bilirubin
Total bilirubin (Âµmol/L)
Alkaline Phosphatase
y-GT
Albumin
Creatinine (mg/dL)
Creatinine (Âµmol/L)
INR
Platelets
IgG
IgM
IgA
yGlobulins
ANA
ANA (IFT) titer 1:
ANA (ELISA)
ANA (Immunoblot)
AMA
AMA (IFT) titer 1:
AMA (ELISA)
AMA (Immunoblot)
SMA
SMA (IFT) titer 1:
SMA (ELISA)
SMA (Immunoblot)
LKM
LKM (IFT) titer:
LKM-1 (ELISA)
LKM (Immunoblot)
SLA/LP (ELISA)
SLA/LP (ELISA)
SLA/LP (Immunoblot)
Other autoantibodies
Other antibodies:
Bone Mineral Density (DXA)
Date of DXA
Lowest T-Score (right or left femur, please add minus in case of negative value)
Lowest T-Score (lumber spine, please add minus in case of negative value)
Biosamples stored
Liver tissue
Serum
Paxgene
Other biosamples:
Prednisolone/Prednisone
Prednisolone/Prednisone dose
Primary indication
Budesonide
Budesonide dose
Primary indication
Azathioprine
Azathioprine dose
Primary indication
UDCA
Other immunosuppression
Mercaptopurine (6-MP)
6-MP dose
Primary indication
MMF
MMF dose
Primary indication
Infliximab
Primary indication
Tacrolimus
Primary indication
Cyclosporin A
Primary indication
Rituximab
Primary indication
Everolimus
Primary indication
Other
Contact Consent
Year of birth
Date of diagnosis
Age at diagnosis
Additional diagnosis of AIH
Weight
Height
BMI
Sex
Ethnicity
Other ethnicity
Alcohol
Smoking
is_smoker
Smoking amount
First degree relative with autoimmune liver disease
Type of autoimmune liver disease
Full simplified AIH score available
Simplified AIH score
Liver biopsy
Date of liver biopsy
Desmet and Scheuer classification assessed?
Fibrosis stage (Desmet and Scheuer)
Grading (Scheuer)
Ishak score assessed?
Fibrosis stage (Ishak)
mHAI
Nakanuma score assessed?
Cholangitis activity
Hepatitis activity
Calculate naknuma grading
Nakanuma grading score
Fibrosis
Bile duct loss
Deposition of orcein positive granules
Calculate naknuma staging
Nakanuma staging score
Additional signs of NAFLD?
Additional signs of NASH?
Transient elastography (Fibroscan)
Liver stiffness (Fibroscan)
Interquartile range (IQR)
Spleen size (diameter)
Tanner stage (1-5, male genital or female breast)
Tanner stage (1-5, pubic hair)
More than 75% school attendance per year
Liver-related complications
Liver imaging consistent with cirrhosis
Ascites
Esophageal or gastric varices
Variceal bleeding
Overt encephalopathy
Hepatorenal syndrome
Pruritus
AST
ALT
Total bilirubin (mg/dL)
Total bilirubin (umol/L)
Alkaline Phosphatase
y-GT
Albumin
Creatinine
Creatinine
INR
Platelets
IgG
IgM
IgA
yGlobulins
ANA
ANA (IFT) titer 1:
ANA (ELISA)
ANA (Immunoblot)
SMA
SMA (IFT) titer 1:
SMA (ELISA)
SMA (Immunoblot)
LKM
LKM (IFT) titer 1:
LKM-1 (ELISA)
LKM (Immunoblot)
SLA/LP (ELISA)
SLA/LP
SLA/LP (Immunoblot)
AMA
AMA (IFT) titer 1:
AMA (ELISA)
AMA (Immunoblot)
PBC specific ANA on IFT
IFT pattern (nuclear rim or nuclear dots)
gp210 (ELISA)
gp210 (Immunoblot)
SP100 (ELISA)
SP100 (Immunoblot)
Bone Mineral Density (DXA)
Date of DXA
Lowest T-Score (right or left femur, please add minus in case of negative value)
Lowest T-Score (lumber spine, please add minus in case of negative value)
Biosamples stored
Liver tissue
Serum
Paxgene
Other biosamples:
UDCA
UDCA dose
UDCA dose mg / kg
Other treatment
Obeticholic acid (OCA)
OCA dose
Prednisolone/Prednisone
Prednisolone/Prednisone dose
Primary indication
Budesonide
Budesonide dose
Primary indication
Azathioprine
Azathioprine dose
Primary indication
Fibrate
Fenofibrate
Bezafibrate
Other:
Other immunosuppression
Mercaptopurine (6-MP)
6-MP dose
Primary indication
MMF
MMF dose
Primary indication
Infliximab
Primary indication
Tacrolimus
Primary indication
Cyclosporin A
Primary indication
Rituximab
Primary indication
Everolimus
Primary indication
Other
Contact consent
Year of birth
Date of diagnosis
Age at diagnosis
Type of bile duct affection
Additional diagnosis of AIH
Date of AIH diagnosis
Weight
Height
BMI
Sex
Ethnicity
Other ethnicity
Alcohol per day
Smoking
is_smoker
Smoking amount (pack years)
First degree relative with autoimmune liver diseases
Type of autoimmune liver disease
Full simplified AIH score available
Simplified AIH score
Liver biopsy
Date of liver biopsy
Desmet and Scheuer classification assessed
Fibrosis stage (Desmet and Scheuer)
Grading (Scheuer)
Ishak score assessed
Fibrosis stage (Ishak)
mHAI
Nakanuma score assessed
Cholangitis activity
Hepatitis activity
Calculate nakanuma grade
Nakanuma grading score
Fibrosis
Bile duct loss
Deposition of orcein positive granules
Calculate nakanuma score
Nakanuma grading score
Additional signs of NAFLD?
Additional signs of NASH?
MRCP
ERCP
PTCD
ERCP/PTCD performed
Dilation therapy
Brushing/biopsy
Cholangioscopy
Transient elastography (Fibroscan)
Liver stiffness (Fibroscan)
Interquartile range (IQR)
Spleen size
Colonoscopy
IBD Status
Biopsy performed?
Date of IBD diagnosis
IBD in histological remission
Histology colon biopsy
Tanner stage (1-5 male genital or female breast)
Tanner stage (1-5 pubic hair)
More than 75% school attendance over the year?
AST
ALT
Total bilirubin (mg/dl)
Total bilirubin (umol/L)
Alkaline Phosphatase
yGT
Albumin
Creatinine
Creatinine
INR
Platelets
IgG
IgM
IgA
yGlobulins
IgG4
ANA
ANA (IFT) titer 1:
ANA (ELISA)
ANA (Immunoblot)
SMA
SMA (IFT) titer 1:
SMA (ELISA)
SMA (Immunoblot)
LKM
LKM (IFT) titer 1:
LKM-1 (ELISA)
LKM (Immunoblot)
SLA/LP (ELISA)
SLA/LP (units)
SLA/LP (Immunoblot)
AMA
AMA (IFT) titer 1:
AMA (ELISA)
AMA (Immunoblot)
Other antibodies:
Bone Mineral Density (DXA)
Date of DXA
Lowest T-Score (right or left femur, please add minus in case of negative value)
Lowest T-Score (lumber spine, please add minus in case of negative value)
Biosamples stored
Liver tissue
Serum
Paxgene
Other biosamples:
UDCA
UDCA dose
Other treatment
Prednisolone/Prednisone
Prednisolone/Prednisone dose
Primary indication
Budesonide
Budesonide dose
Primary indication
Azathioprine
Azathioprine dose
Primary indication
Infliximab
Primary indication
Adalimumab
Primary indication
Vedolizumab
Primary indication
Ustekinumab
Primary indication
Other:
Other immunosuppression
Mercaptopurine (6-MP)
6-MP dose
Primary indication
MMF
MMF dose
Primary indication
Tacrolimus
Primary indication
Cyclosporin A
Primary indication
Rituximab
Primary indication
Everolimus
Primary indication
Other
Liver-related complications / signs of cirrhosis
Liver imaging consistent with cirrhosis
Ascites
Esophageal or gastric varices
Variceal bleeding
Overt encephalopathy
Hepatorenal syndrome
Cholangitis (Clinical diagnosis requires antibiotic use)
Hepatobiliary Malignancy
Date hepatobiliary malignancy
Hepatobiliary malignancy type
Cholecystectomy (CHE)
Date CHE
CHE indication
Colectomy
Date colectomy
Main indication for colectomy
Pruritus
AST
ALT
Total bilirubin (mg/dL)
Total bilirubin (Âµmol/L)
Alkaline Phosphatase
y-GT
Albumin
Creatinine (mg/dL)
Creatinine (Âµmol/L)
INR
Platelets
IgG
IgM
IgA
yGlobulins
Change of treatment regimen (other than dose change)
remark
Azathioprine
Reason for change
Date of drug withdrawal
Prednisolone/Prednisone
Reason for change
Date of drug withdrawal
Budesonide
Reason for change
Date of drug withdrawal
Mercaptopurine (6-MP)
Reason for change
Date of drug withdrawal
Tacrolimus
Reason for change
Date of drug withdrawal
MMF
Reason for change
Date of drug withdrawal
remark
Prednisolone/Prednisone
Prednisolone/Prednisone dose
Primary indication
Budesonide
Budesonide dose
Primary indication
Azathioprine
Azathioprine dose
Primary indication
Azathioprine metabolites
6-TGN
6-TGN (pmol/0.2ml)
MMP
MMP (pmol/0.2ml)
UDCA
psc pbc diag
UDCA dose
Other immunosuppression
Mercaptopurine (6-MP)
6-MP dose
Primary indication
MMF
MMF dose
Primary indication
Tacrolimus
Primary indication
Cyclosporin A
Primary indication
Infliximab
Primary indication
Rituximab
Primary indication
Everolimus
Primary indication
Other
PSC specific treatment
Adalimumab
Primary indication
Vedolizumab
Primary indication
Ustekinumab
Primary indication
PBC specific treatment
Obeticholic acid (OCA)
OCA dose
Fibrate
Fenofibrate
Bezafibrate
Date of follow-up
date_check_6mo
Date check
Liver-related complications / signs of cirrhosis
Liver imaging consistent with cirrhosis
Date liver imaging consistent with cirrhosis
Ascites
Date ascites
Esophageal or gastric varices
Date of endoscopy
Variceal bleeding
Date of variceal bleeding
Overt encephalopathy
Date encephalopathy
Hepatorenal syndrome
Date hepatorenal syndrome
Liver transplantation
Liver transplantation date
Indication of liver transplantation
Hepatobiliary malignancy
Date of hepatobiliary malignancy
Type of hepatobiliary malignancy
Other malignancy
Type of other malignancy
Date of other malignancy
New diagnosis of PBC
Date of new diagnosis of PBC
New diagnosis of PSC
Date of new diagnosis of PSC
MRCP
Weight
Height
BMI
Tanner stage (1-5 for male genital or female breast)
Tanner stage (1-5 pubic hair)
add_report_button
add_report_button
add_report_button
AST
ALT
Total bilirubin
Total bilirubin (umol/L)
Alkaline Phosphatase
yGT
Albumin
Creatinine
Creatinine
INR
Platelets
IgG
IgM
IgA
yGlobulins
ANA
ANA (IFT) titer 1:
ANA (ELISA)
ANA (Immunoblot)
SMA
SMA (IFT) titer 1:
SMA (ELISA)
SMA (Immunoblot)
LKM
LKM (IFT) titer 1:
LKM-1 (ELISA)
LKM (Immunoblot)
SLA/LP (ELISA)
SLA/LP (units)
SLA/LP (Immunoblot)
AMA
AMA (IFT) titer 1:
AMA (ELISA)
AMA (Immunoblot)
Other antibodies:
Biosamples stored
Liver tissue
Serum
Paxgene
Other biosamples:
Colonoscopy
IBD Status
Biopsy performed?
Date of biopsy
Histology colon biopsy
IBD in histological remission
Ultrasound
MRI
Date of follow-up
Age at follow-up
Bone mineral density (DXA)
Date of DXA
Lowest T-Score (right or left femur, please add minus, in case of negative value)
Lowest T-Score (lumber spine, please add minus in case of negative value)
Transient elastography (Fibroscan)
Liver stiffness (Fibroscan)
Interquartile range (IQR)
Liver biopsy
Date of liver biopsy
Desmet and Scheuer classification assessed
Fibrosis stage (Desmet and Scheuer)
Grading (Scheuer)
Ishak Score assessed
Fibrosis stage (Ishak)
mHAI
Nakanuma score assessed
Cholangitis activity
Hepatitis activity
Calculate nakanuma grading
Nakanuma grading score
Fibrosis
Bile duct loss
Deposition of orcein positive granules
Calculate nakanuma staging
Nakanuma staging score
Additional signs of NAFLD?
Additional signs of NASH?
Liver-related outcome / complications
Spleen size (diameter)
Date spleen size
Liver imaging consistent with cirrhosis
Date liver imaging
Ascites
Date ascites
Esophageal or gastric varices
Date esophageal or gastric varices
Variceal bleeding
Date variceal bleeding
Overt encephalopathy
Date encephallopathy
Hepatorenal syndrome
Date hepatorenal syndrome
Cholangitis (clinical diagnosis requires antibiotics)
Date cholangitis
Hepatobiliary malignancy
Date hepatobiliary malignancy
Hepatobiliary malignancy type
Other malignancy
Type of other malignancy
Date of other malignancy
Cholecystectomy (CHE)
Date CHE
Indication CHE
Colectomy
Date colectomy
Main indication for colectomy
Pruritus
Liver transplantation
Date of liver transplantation
Indication liver transplantation
New diagnosis of AIH
Date new diagnosis of AIH
Weight
Height
BMI
Tanner stage (1-5 male genital or female breast)
Tanner stage (1-5, pubic hair)
More than 75% school attendance over the year?
ESPGHAN Score
Is female
Pregnancy during last 12 months
AIH_check
UDCA
UDCA dose
Other treatment
Prednisolone/Prednisone
Prednisolone/Prednisone dose
Primary indication
Budesonide
Budesonide dose
Primary indication
Azathioprine
Azathioprine dose
Primary indication
aza_aih check
Azathioprine metabolites assessed
6-TGN
6-TGN (pmol/0.2ml)
MMP
MMP (pmol/0.2ml)
Infliximab
Primary indication
Adalimumab
Primary indication
Vedolizumab
Primary indication
Ustekinumab
Primary indication
Other:
ERCP within last 12 months
PTCD within last 12 months
ERCP/PTCD performed
Dilation therapy
Brushing/Biopsy
Cholangioscopy
AIH specific treatment
Change of immunosuppressive regimen (other than dose change)
Drugs used and stopped during past 12 months
Azathioprine
Reason for change
Date of drug withdrawal
Prednisolone/Prednisone
Reason for change
Date of drug withdrawal
Budesonide
Reason for change
Date of drug withdrawal
Mercaptopurine (6-MP)
Reason for change
Date of drug withdrawal
Tacrolimus
Reason for change
Date of drug withdrawal
MMF
Reason for change
Date of drug withdrawal
Current AIH-specific treament
Mercaptopurine (6-MP)
6-MP dose
Primary indication
MMF
MMF dose
Primary indication
Tacrolimus
Primary indication
Cyclosporin A
Primary indication
Rituximab
Primary indication
Everolimus
Primary indication
Other
AST
ALT
Total bilirubin (mg/dL)
Total bilirubin (Âµmol/L)
Alkaline Phosphatase
y-GT
Albumin
Creatinine (mg/dL)
Creatinine  (Âµmol/L)
INR
Platelets
IgG
IgM
IgA
yGlobulins
ANA
ANA (IFT) titer 1:
ANA (ELISA)
ANA (Immunoblot)
AMA
AMA (IFT) titer 1:
AMA (ELISA)
AMA (Immunoblot)
SMA
SMA (IFT) titer 1:
SMA (ELISA)
SMA (Immunoblot)
LKM
LKM (IFT) titer:
LKM-1 (ELISA)
LKM (Immunoblot)
SLA/LP (ELISA)
SLA/LP (ELISA)
SLA/LP (Immunoblot)
Other autoantibodies
Other antibodies:
Biosamples stored
Liver tissue
Serum
Paxgene
Other biosamples:
Date of follow-up
Age at follow-up
Bone mineral density (DXA)
Date of DXA
T-Score (right or left femur, please add minus in case of negative value)
T-Score (lumber spine, please add minus in case of negative value)
Transient elastography (Fibroscan)
Liver stiffness
Interquartile range (IQR)
Spleen size (diameter)
MRCP
Weight
Height
BMI
Tanner stage (1-5 for male genital or female breast)
Tanner stage (1-5, pubic hair)
More than 75% school attendance over the year?
ESPGHAN Score
Is female
Pregnancy during last 12 months
Follow-up liver biopsy
Date follow-up biopsy
Desmet and Scheuer classification assessed?
Fibrosis stage (Desmet and Scheuer)
Grade (Scheuer)
Ishak score assessed?
Fibrosis stage (Ishak)
mHAI
Nakanuma score assessed?
Cholangitis activity
Hepatitis activity
Calculate Nakanuma grading?
Nakanuma grading score
Fibrosis
Bile duct loss
Deposition of orcein positive granules
Calculate Nakanuma scoring?
Nakanuma staging score
Additional signs of NAFLD?
Additional signs of NASH?
Liver-related complications / signs of cirrhosis
Liver imaging consistent with cirrhosis
Date imaging consistent with cirrhosis
Ascites
Date Ascites
Esophageal or gastric varices
Date of esophageal or gastric varices
Variceal bleeding
Date of variceal bleeding
Overt encephalopathy
Date encephalopathy
Hepatorenal syndrome
Date hepatorenal syndrome
Liver transplantation
Liver transplantation date
Indication of liver transplantation
Hepatobiliary malignancy
Date of hepatobiliary malignancy
Type of hepatobiliary malignancy
Other malignancy
Type of other malignancy
Date of other malignancy
Additional diagnosis of PBC
Date of new diagnosis of PBC
Additional diagnosis of PSC
Date of new diagnosis of PSC
Change of immunosuppressive regimen (other than dose change)
Drugs used and stopped during past 12 months
Azathioprine
Reason for change
Date of drug withdrawal
Prednisolone/Prednisone
Reason for change
Date of drug withdrawal
Budesonide
Reason for change
Date of drug withdrawal
Mercaptopurine (6-MP)
Reason for change
Date of drug withdrawal
Tacrolimus
Reason for change
Date of drug withdrawal
MMF
Reason for change
Date of drug withdrawal
Current treatment
Prednisolone/Prednisone
Prednisolone/Prednisone dose
Primary indication
Budesonide
Budesonide dose
Primary indication
Azathioprine
Azathioprine dose
Primary indication
Azathioprine metabolites assessed
6-TGN
6-TGN (pmol/0.2ml)
MMP
MMP (pmol/0.2ml)
UDCA
Other immunosuppression
Mercaptopurine (6-MP)
6-MP dose
Primary indication
MMF
MMF dose
Primary indication
Tacrolimus
Primary indication
Cyclosporin A
Primary indication
Infliximab
Primary indication
Rituximab
Primary indication
Everolimus
Primary indication
Other
PBC check
PBC specific treatment
Obeticholic acid (OCA)
OCA dose
Fibrate
Fenofibrate
Bezafibrate
psc check
PSC specific treatment
Adalimumab
Primary indication
Vedolizumab
Primary indication
Ustekinumab
Primary indication
ERCP or PTCD within last 12 months
Dilation therapy
Brushing/Biopsy
Cholangioscopy
AST
ALT
Total bilirubin (mg/dL)
Total bilirubin (umol/L)
Alkaline Phosphatase
yGT
Albumin
Creatinine
Creatinine
INR
Platelets
IgG
IgM
IgA
yGlobulins
ANA
ANA (IFT) titer 1:
ANA (ELISA)
ANA (Immunoblot)
SMA
SMA (IFT) titer 1:
SMA (ELISA)
SMA (Immunoblot)
LKM
LKM (IFT) titer 1:
LKM-1 (ELISA)
LKM (Immunoblot)
SLA/LP (ELISA)
SLA/LP
SLA/LP (Immunoblot)
AMA
AMA (IFT) titer 1:
AMA (ELISA)
AMA (Immunoblot)
PBC specific ANA on IFT
IFT pattern (nuclear rim or nuclear dots)
gp210 (ELISA)
gp210 (Immunoblot)
SP100 (ELISA)
SP100 (Immunoblot)
Biosamples stored
Liver tissue
Serum
Paxgene
Other biosamples:
Date of Follow-up
Age at follow-up
Bone mineral density (DXA)
Date of DXA
Lowest T-Score (right or left femur, please add minus in case of negative value)
Lowest T-Score (lumber spine, please add minus in case of negative value)
Transient elastography (Fibroscan)
Liver stiffness (Fibroscan)
Interquartile range (IQR)
Liver biopsy
Date of liver biopsy
Desmet and Scheuer classification assessed?
Fibrosis stage (Desmet and Scheuer)
Grade (Scheuer)
Ishak score assessed?
Fibrosis stage (Ishak)
mHAI
Nakanuma score assessed?
Cholangitis activity
Hepatitis activity
Calculate nakanuma grading
Nakanuma grading score
Fibrosis
Bile duct loss
Deposition of orcein positive granules
Calculate nakanuma staging
Nakanuma staging score
Additional signs of NAFLD?
Additional signs of NASH?
Liver-related complications / signs of cirrhosis
Liver imaging consistent with cirrhosis
Date of imaging consistent with cirrhosis
Ascites
Date ascites
Esophageal or gastric varices
Date esophageal or gastric varices
Variceal bleeding
Date variceal bleeding
Overt encephalopathy
Date encephalopathy
Hepatorenal syndrome
Date hepatorenal syndrome
Liver transplantation
Date of liver transplantation
Indication for liver transplantation
Hepatobiliary malignancy
Date hepatobiliary malignancy
Hepatobiliary malignancy type
Other malignancy
Type of other malignancy
Date of other malignancy
Pruritus
Additional diagnosis of AIH
Date of new diagnosis AIH
Weight
Height
BMI
Tanner stage (1-5, male genital or female breast)
Tanner stage (1-5, pubic hair)
More than 75% school attendance per year
Is female
Pregnancy during last 12 months
UDCA
UDCA dose
Other treatment
Obeticholic acid (OCA)
OCA dose
Prednisolone/Prednisone
Prednisolone/Prednisone dose
Primary indication
Budesonide
Budesonide dose
Primary indication
Azathioprine
Azathioprine dose
Primary indication
Azathioprine metabolites assessed
6-TGN
6-TGN (pmol/0.2ml)
MMP
MMP (pmol/0.2ml)
Fibrate
Fenofibrate
Bezafibrate
Other:
AIH check
AIH specific treatment
Change of immunosuppressive regimen (other than dose change)
Drugs used and stopped during past 12 months
Azathioprine
Reason for change
Date of drug withdrawal
Prednisolone/Prednisone
Reason for change
Date of drug withdrawal
Budesonide
Reason for change
Date of drug withdrawal
Mercaptopurine (6-MP)
Reason for change
Date of drug withdrawal
Tacrolimus
Reason for change
Date of drug withdrawal
MMF
Reason for change
Date of drug withdrawal
Current AIH-specific treatment
Mercaptopurine (6-MP)
6-MP dose
Primary indication
MMF
MMF dose
Primary indication
Tacrolimus
Primary indication
Cyclosporin A
Primary indication
Infliximab
Primary indication
Rituximab
Primary indication
Everolimus
Primary indication
Other
Inclusion criteria
For Portal vein thrombosis
Specify Other Vascular Disease
Exclusion criteria
Date of first diagnosis
Initials
Birth date
Gender
Country of birth
Country of study
Comments
Informed consent form approved and signed
Inclusion in the study
Date of inclusion or screen failure
Date of visit
Time period between onset of symptoms and diagnosis
Clinical Examination
Asymptomatic
Systolic blood pressue
Diastolic pressue
Heart rate
Weight
Waist size
Height
Estimated weight without ascites and oedema
Fever 38Â°C
Abdominal pain
Ascites
asc_check
Ascites response to diuretics
Hepatic encephalopoathy
Oedema of lower limbs
Spontaneous bacterial peritonitis
Hepatorenal syndrome
Hepatopulmonary syndrome
Other symptoms
Endoscopy
Upper endoscopy
Esophageal varices
Grade
Esophagel varices red color signs
Gastric varices
Gastro-intestinal bleeding
Gastro-intestinal bleeding date
Gastro-intestinal bleeding origin
Portopulmonary hypertension
If there was a significant delay in diagnosis, did the patient have a history of liver disease and present with decompensations?
Ascites
Hepatic encephalopathy
Is she still menstruated?
Alcohol use
Average grams of ethanol per week
Smoking
Smoker
Number of pack years
Medications and comorbidities
Medications
CID of drug(s)
Comorbidity at time of diagnosis
Cirrhosis
Biopsie proven cirrhosis
AC VHC
Ag HBs
Diabetes
HTA
Systemic disease (other than acquired prothrombotic)
Sarcoidosis
Connective Tissue Disease
Vasculitis
Celiac Disease
Other comorbidity disorders
Number of inconclusive abdominal imaging performed between onset of manifestations and diagnosis
Type of imaging studies performed confirming diagnosis
Ultrasound
Doppler
CT
Hepatic venography
MRI
Cholangio MRI
Liver
Diffuse harmonious enlargement
Atrophy / hypertrophy complex
Abnormal perfusion pattern at triphasic contrast enhancement (CT or MRI)
Budd-Chiari type nodules or HNF like
Largest nodule size
Number of nodules
Bile ducts
Hepatic Veins (HV)
Number of veins seen fully patent and normal
Short length stenosis (
Intrahepatic or subcapsular hepatic vein collaterals
Abnormal Doppler flow pattern in more than one large vein
Inferior vena cava
Aspect
check_ivc
Level of obstruction
Portal vein
Portal vein occlusion
Portal vein occlusion type
Longitudinal assessment: portal vein bifurcation
Longitudinal assessment: portal vein origin
Direction of flow
Right portal vein branch
Right portal vein branch
Right portal vein direction of flow
Left portal vein branch
Left portal vein branch
Left portal vein direction of flow
Splenic vein
Superior mesenteric vein
Portoportal cavernoma
Portosystemic collaterals
Hepatic artery
Dilatation
Hepatic artery resistance index
Spleen
Splenectomy
Spleen size
Maximal spleen length
Ascites
Ascites degree
Pleural effusion
Haemodynamic studies
Hepatic Vein Catheterization
Swan-Ganz
Date of measurement
Right atrium
Supra hepatic IVC Before TIPS
Supra hepatic IVC After TIPS
Infrahepatic IVC
Free hepatic vein Before TIPS
Free hepatic vein After TIPS
Wedged hepatic vein
Hepatic venous pressure gradient Before TIPS
Hepatic venous pressure gradient After TIPS
Hepatic vein upstream from a short-length stenosis
Free pulmonary artery pressure
Wedged pulmonary artery pressure
Cardiac output
Portal pressure Before TIPS
Portal pressure After TIPS
Fibroscan
Fibroscan at diagnosis
Date of Fibroscan
Fibroscan: Number of valid measurements
Fibroscan: Total number of measurements
Fibroscan: CAP
IQR
Number of conclusive abdominal imaging performed
Liver Biopsy
Liver biopsy performed
Consentment obtained using remnant biopsy
Date of liver biopsy
Liver biopsy local number
Liver biopsy type
Frozen liver biopsy obtained?
EDTA Blood
EDTA sample obtained?
EDTA sample date
Buffy coat
Buffy coat sample obtained ?
Buffy coat sample date
Number
CRB Number
DNA sample
DNA sample obtained?
DNA sample date
Number
CRB Number
Plasma
Plasma sample obtained?
Plasma sample date
Number
CRB Number
Use of anticoagulants
Other anticoagulants used
Use antiplatelet
Serum
Serum sample obtained?
Serum sample date
Number
Urine
Urine sample obtained?
Urine sample date
Stool
Stool sample obtained?
Stool sample date
Date of evaluation
Inherited thrombophilia
Factor V leiden mutation
Mutation type
APC resistance
Prothrombin (G20210A) mutation
Protein C activity decreased?
Protein C deficiency activity
Protein C mutation
Abnormal prothrombin time at testing
use of anticoagulation at testing
type of anticoagulation
Protein S decreased activity?
Protein S mutation
Protein S deficiency activity (%)
Abnormal prothrombin time
Acquired thrombophilia
factor X
factor II
use of anticoagulation at testing
type of anticoagulation
Use of oral contraceptives at testing
Antithrombin decreased activity
Antithrombin deficiency activity
Antithrombin mutation
Abnormal prothrombin time
JAK 2 Mutation (V617F)
JAK 2 Exon-12
CALR mutation
MPL mutation (myeloproliferative leukemia)
% of mutated allele
EPO Value
Bone marrow biopsy
Type of MPD
Culture of erythroid progenitors
Antiphospholipid syndrome tested
Lupus anticoagulant antibody
Anticardiolipin antibody
Antibeta2GP1 antibody
Confirmed APS
Methionine tolerance test
Level of plasma homocysteine at fasting (umol/l)
Evidence for hyperhomocysteinemia
Homozygous MTHFR-C677T mutation
Vitamin deficiency/ folic acid excluded
anti-transglutaminase antibodies
Paroxysmal nocturnal hemoglobinuria: CD55 and CD59 deficient clone at flow cytometry
Behcet's disease
Recurrent genital ulceration
Eye lesions
Skin lesions
Pathergy test
Telomeropathy
Type of telomeropathy
IgM CMV
PCR CMV
Angiotensin-converting enzyme level
Hormonal Risk Factors
Pregnancy

Date of last delivery/abortion
Number of miscarriages
Comments
Hormononal Contraception
Type of Used Hormonal Contraception prior to diagnosis
Use of oral contraceptives prior to diagnosis
History of medically assisted reproduction
Date of medically assisted reproduction
contra_check
Type at onset of manifestations
Date start of use
Ongoing
Date end of use
Other general factors
Systemic disease (other than acquired prothrombotic)
Condition(s)
Other potential aetiological factors Condition(s)
Local Precipitating Factors Prior to Diagnosis
Abdominal trauma
Date of abdominal trauma
Abdominal intervention
Date of procedure
Type
Splenectomy
Date of Splenectomy
Cholecystectomy
Date of Cholecystectomy
Hepatobiliary Surgery
Date of Hepabiliary Surgery
TIPS
Date of TIPS
Sclerotherapy
Date of Sclerotherapy
LTx
Date of LTx
Other
Date of Other Intervention
Abdominal infection/inflamation
Date of abdominal infection/inflamation
Type of abdominal infection/inflamation
Pancreatitis
Date of Pancreatitis
Diverticulitis
Date of Diverticulitis
Appendicitis
Date of Appendicitis
Other Infection / Inflammation
Date of Other Infection / Inflammation
Extra-abdominal infection/inflamation
Date
Type
Personal history of thrombosis
Mesenterico-portal venous system
Date
Budd-Chiari syndrome
Date
Non cirrhotic idiopathic portal hypertension
Date
Venous thrombosis elsewhere
Arterial thrombosis
Familial history of thrombosis
History of thrombotic events in relatives
Closest degree of affected relatives
Date of Evaluation
Red blood cell count
Haemoglobin
Haematocrit
Leukocytes
Neutrophils
Eosinophils
Lymphocytes
Platelet count
Deviant Laboratory Date
Prothrombin time
Prothrombin time (normal value)
Prothrombin time
Prothrombin time
Antinuclear antibodies
Antinuclear antibodies value
ALT
ALT normal value
AST
AST normal value
Alkaline phosphatase
Alkaline phosphatase normal value
GGT
GGT normal value
Serum albumin
Serum albumin normal value
Serum gamma-globulins IgG
Serum gamma-globulins normal value
Serum Bilirubin Unit
Serum bilirubin
Serum bilirubin
Serum ferritin
Factor VIII
Factor VII
Factor V
Serum Creatinine Unit
Serum creatinine
Serum creatinine
Serum sodium value
Fasting Serum Glucose Unit
Fasting serum glucose value
Fasting serum glucose value
Fasting serum triglycerides value
C-Reactive protein
Serum alfa foetoprotein
Serum alfa foetoprotein normal value
Cholesterol T
Cholesterol HDL
Cholesterol LDL
Insulinemia
Glycated hemoglobin
urine sodium value - 24 hour
Ascites
Albumin
Total protein
Polymorphonuclear neutrophils
Medications
Add Follow-up
Reason for Study Termination
Date of Last Contact
Dead?
Did death occur?
Date of death
Cause of death
Other cause:
Autopsy performed
Was a liver transplantation performed?
Date of liver transplantation
Why was no liver transplantation performed?
Other reason:
Death after liver transplantation?
Lifespan after transplantation:
Date of follow-up
Gastrointestinal bleeding
Encephalopathy
Acute renal failure
Severe bacterial infection
Primary liver cancer
Thrombotic event
Biliary symptoms
Main events
Anticoagulation was permanently stopped
Date of interruption
Anticoagulation was first initiated
Date of initiation
First angioplasty/stenting of HV or IVC
Date of stenting
Thrombolysis
First TIPS
Date of TIPS
First liver transplantation
Date of transplantation
First surgical portosystemic shunting
Date of shunt
Revision of TIPS or angioplasty
Date of revision
Pregnancy
Start date of pregnancy
Date of delivery
Portal recanalization
Date of portal recanalization
Patients with TIPS
Was a TIPS inserted during the previous FU period
Date of evaluation
Clinical dysfunction
Hemodynamic (but not clinical) dysfunction
Radiological dysfunction
Salvage procedure
Type of procedure
Date of salvage procedure
Patients with angioplasty/stenting
Was a angioplasty/stenting performed in a previous f-u period
Date of evaluation
Clinical dysfunction
Hemodynamic (but not clinical) dysfunction
Radiological dysfunction
Salvage procedure
Type of procedure
Date of salvage procedure
Patients with surgical shunt
Was a surgical shunt constructed in a previous f-u period
Date of evaluation
Clinical dysfunction
Hemodynamic (but not clinical) dysfunction
Radiological dysfunction
Salvage procedure
Type of procedure
Date of salvage procedure
Comments
Before the procedure
Date of evaluation
Ascites volume
Ascites severity value
Encephalopathy value
Haemoglobin value
Haematocrit value
Leukocytes value
Platelet count value
Prothrombin time value
Prothrombin time normal value
Prothrombin time value
Prothrombin time normal value
Prothrombin time value
Prothrombin time normal value
ALT value
ALT normal value
AST value
AST normal value
Alkaline phosphatase value
Alkaline phosphatase normal value
Serum albumin value
Serum albumin normal value
Serum bilirubin unit
Serum bilirubin value
Serum bilirubin value
Factor V value
Serum creatinine unit
Serum creatinine value
Serum creatinine value
Serum sodium value
CRP
Serum alfa foetoprotein value
Serum alfa foetoprotein normal value
Cholesterol T
Cholesterol HDL
Cholesterol LDL
Insulinemia
Glycated hemoglobin
Last evaluation in f-u period
Date of evaluation
Ascites volume
Ascites severity
Encephalopathy
Haemoglobin value
Haematocrit value
Leukocytes value
Platelet count value
Prothrombin time value
Prothrombin time normal value
Prothrombin time value
Prothrombin time normal value
Prothrombin time value
Prothrombin time normal value
ALT value
ALT normal value
AST value
AST normal value
Alkaline phosphatase value
Alkaline phosphatase normal value
Serum albumin value
Serum albumin normal value
Serum bilirubin unit
Serum bilirubin value
Serum bilirubin value
Factor V value
Serum creatinine unit
Serum creatinine value
Serum creatinine value
Serum sodium value
CRP
Serum alfa foetoprotein value
Serum alfa foetoprotein normal value
Just before the procedure
Date of evaluation
CT or IRM
Inferior vena cava patent
Main portal vein patent
Right portal vein branch patent
Left portal vein branch patent
Direction of portal flow
Superior mesenteric vein patent
Splenic vein patent
Cavernoma
Splenic vein patent
MRI documented cholangiopathy
Fibroscan value
value
IQR
Ascites
Last evaluation in f-u period
Date of evaluation
CT or IRM
Inferior vena cava patent
Main portal vein patent
Right portal vein branch patent
Left portal vein branch patent
Direction of portal flow
Superior mesenteric vein patent
Splenic vein patent
Cavernoma
BCS-type, or HNF-like, nodules
MRI documented cholangiopathy
Fibroscan
Liver fibroscan
IQR
Date of fibroscan
Fibroscan: Number of valid measurements
Fibroscan: Total number of measurements
CAP
Ascites
Date of evaluation
Mesenteric infarction
Bowel resection
Splenic infarction
Topic of Comment
Comment
Type of medication
Other, please specify type of medication
Medication (anticoagulation)
Medication (diuretic)
Medication (antiplatelet)
Medication (blocker)
med_check
Medication (generic name)
Daily Dose
Unit







[Control]
[Control]
[Control]
[Control]
[Control]
[Control]
[Control]
[Control]
[Control]




































































Which criteria does the patient fullfill to be included in the registry?
Is the age (years) at which the patient was diagnosed with this benign tumour known?
What was the patient's age (years) at diagnosis of this benign tumour?
Where is the benign neoplasm located?
What is the maximal number of these polyps ever observed in this patient?
What is the dominant polyp type?
What is the maximal number of vestibular schwannomas ever observed in this patient?
What is the laterality of the vestibular schwannoma(s)?
What is the maximal number of meningiomas ever observed in this patient?
What is the maximal number of ependymomas ever observed in this patient?
What is level of evidence for the diagnosis?


Gene (cosmic)
What is the g. notation? (HGVS nomenclature)
Genome build
What is the coding DNA notation? (HGVS nomenclature)
What is the transcript belonging to the cDNA variant? (HGVS nomenclature)
What is the type of mutation?
What is the zygosity of the germline variant?
What is the class of the variant?


Which criteria does the patient fullfill to be included in the registry?
Is the age (years) at which the patient was diagnosed with this malignancy known?
At what age (years) was the patient diagnosed with this malignancy?
Where is the malignancy located?
What is the morphology of this malignancy?
What is the Estrogen receptor status of the breast cancer?
What is the Progesteron receptor status of the breast cancer?
What is the Her2Neu receptor status of the breast cancer?
What is the laterality of the breast cancer?
What is the mammographic density?
What is the level of evidence for the diagnosis?
Has IHC of the MMR protein or microsatellite instability analyses been performed?
What are the results of the IHC of the MMR proteins?
What are the results of the MSA of the tumour DNA?
Has MLH1 promoter hypermethylation testing or tumour BRAF V600E mutation analyses been performed?
What are the results of the somatic MMR mutation analysis?
Which criteria does the patient fullfill to be included in the registry?

What is the local patient pseudonym?
What is the local family pseudonym?
What is the patient's European patient identifier (EUPID)?
Is the year of birth of the patient known?
What is patient’s year of birth? (Specify using 4 digits)
What was the patient's sex at birth?
What is the patient's country of residence?

What is the patient's follow-up status?
Is the year of death of the patient known?
In what year did the patient die?
Is the year of lost to follow up of the patient known?
In what year was the patient lost to follow up?
Is the year of opted-out of the patient known?
In what year has the patient opted out or revoked the GENTURIS registry consent?
What is the date (yyyy-mm-dd) of the last clinical information of the patient?
Has the patient ever had a colonoscopy?
Is the age (years) at which the patient had the last colonoscopy known?
What was the age (years) of the patient at the last colonoscopy?
What clinical data is locally available for this patient?
What material is locally available for this patient?

Has the patient signed consent for the GENTURIS registry?
At what date (yyyy-mm-dd) was the informed consent for the GENTURIS registry signed?
Has the patient signed consent for re-contacting for research purposes?
Has the patient signed informed consent for re-use of data for (other) research purposes?
Has the patient signed informed consent for research using residual tissue?
Has the patient signed informed consent for analyses with the chance of incidental finding? (e.g. open WES)

What is the responsible HCP?
What is the name of the physician in charge of the patient's clinical management within the HCP?
What is the e-mail address of the HCP contact person
At what date (yyyy-mm-dd) was the data entered in the registry?

What was the date (yyyy-mm-dd) of the patients first contact with the specialised/expertise center?
Is the age (years) at which the patient had his/her first symptoms known?
At what age (years) did the patient have his/her first symptoms?

What is the classification (Orphanet) of the rare disease of the patients?
Is this a proband patient or relative?
What is the relation of this patient to the proband?

Has this patient ever had a (invasive or in situ) malignancy?
Multiple malignancy diagnoses can be entered

Has this patient ever had a benign neoplasm/tumour?
Multiple benign neoplasms diagnoses can be entered

Has the patient phenotypical characteristics?
Multiple phenotypes can be entered
Is the maximal number of Cafe au lait spots ever observed in the patient known?
What is the maximal number of cafe au lait spots ever observed in the patient?

Is a genetic test performed?
What kind of genetic testing has been performed?
Which medical laboratory is in charge of the genetic analysis
Has any class 3, 4 of 5 variant been found?
Genetic variants

Has any first degree relative ever had a solid malignancy?
What was the first degree relative(s) age (years) at first diagnosis of the solid malignancy?
Has any second degree relative(s) ever had a solid malignancy?
What was the first degree relative(s) age (years) at first diagnosis of the solid malignancy?
Has the patient a first degree relative with NF1 who has been diagnosed according to the following criteria: Presence of two or more of the following diagnostic criteria in the first degree relative:
1) Six or more café au lait spots (> 5mm in greatest diameter in prepuberal patient  and >15mm in greatest diameter in postpuberal patient)
2) Two or more neurofibromas or one plexiform neurofibromas
3) Axillary or inguinal freckling
4) Optic glioma
5) Two or more lisch nodules (iris hamartomas)
6) A distinct osseous lesion














































something recognizable













Hugo.owl.HGNC_ID
Hugo.owl.Approved_Symbol
Hugo.owl.Approved_Name
Hugo.owl.Aliases
Hugo.owl.Chromosome
Hugo.owl.RefSeq__mapped_data_supplied_by_NCBI_
Hugo.owl.Locus_Type
Hugo.owl.Pubmed_IDs
Hugo.owl.Ensembl_ID__mapped_data_supplied_by_Ensembl_




































































































































































































hgvs notation for this allele. Format (NM_004006.2:c.4375C>T)
COSMIC genes (can be replaced by other list of genes)









Clinical interperation for variant

Record ID

Hospital Name [user-dag-label]
Patient management started at:
Date of first contact with the hospital/registration start
Consent to use clinical data
Consent to use biological data
Date of birth
Education (ISCED classification)
Marital status
Gender
Ethnicity
Country of residence
Weight (kg)
Height (cm)
BMI
Smoking
Smoking habits
Cigarettes/cigars smoked per day
Number of years as a smoker
Pack/year
Pack/year (manual)
Alcohol
Exposure to carcinogens (IARC)
Please specify
Previous cancer
Other head and neck malignant cancers 
Site
Year of diagnosis
Other head and neck benign tumours
Year of diagnosis
Previous radiotherapy at head and neck site
Year of radiotherapy
Previous chemotherapy for head and neck cancer
Year of chemotherapy
Previous anti neoplastic agents for head and neck cancer
Previous anti neoplastic agents type
Year of anti neoplastic agents
Previous oncological head and neck surgery
Year of oncological head and neck surgery
Previous non-oncological head and neck surgery 
Year of non-oncological head and neck surgery
Other malignant cancers different from cancers of head and neck
Please select the malignant cancers different from cancers of head and neck
Please specify
Year of diagnosis
Genetic syndrome
Previous pre cancer lesions
Previous pre cancer lesions
Comorbidity
Choose all present comorbidities
Age
Charlson comorbidity index (CCI) Total points:
Charlson age comorbidity index (CACI) Total points:
Radiotherapy induced
Age at diagnosis (automatic)
Site (AJCC)
Subsite
Subsite
Subsite
Subsite
Histology (WHO 2017)
Squamous subtype
Please specify whether it was SMARCB1 (INI-1)-deficient Sinonasal Carcinoma
Adenocarcinoma subtype
Neuroendocrine subtype
Please specify whether it was SMARCB1 (INI-1)-deficient Sinonasal Carcinoma
Biopsy
Biopsy date
Biopsy done by
Plasmatic EBV DNA at baseline
Primer type
Please specify
Copy Number
HPV status
HPV status detected by
p16
Staging procedures done/requested by
Imaging for primary site
CT
MRI
US
FDG PET
PET with other tracers
Optical digital methods (e.g. narrow-band imaging)
CT/PET
Unknown
Other imaging for primary site
CT
MRI
Imaging for neck
US
FDG PET
PET with other tracers
Optical digital methods (e.g. narrow-band imaging)
CT/PET
Unknown
Other imaging for neck
Imaging for metastatic disease
CT
MRI
US
FDG PET
PET with other tracers
CT/PET
Unknown
Other imaging for metastatic disease
cT
cN
cM
Extranodal extension (ENE)
Clinical staging (automatic) = 0
TESTING Clinical staging (automatic) = 0
If the information on cT,N,M is not available, please include directly the clinical staging here
Clinical staging defined by
Pathological T, N, M
cT
cN
cM
Extranodal extension (ENE)
If the information on cT,N,M is not available, please include directly the clinical staging here
Clinical update
Clinical update date
Month of clinical update
Year of clinical update
Status at last clinical update
AWD, Local
AWD, Regional
AWD, Metastatic
New cancer ICD-O3
Adverse event type (CTCAE Term)
Please specify
Adverse event starting date
Adverse event starting month
Adverse event starting year
Adverse event ongoing
Adverse event end date
Adverse event ending month
Adverse event ending year
Adverse events grade (CTCAE v5)
Adverse event type (CTCAE Term)
Please specify
Second adverse event starting date
Second adverse event starting month
Second adverse event starting year
Second adverse event ongoing
Second adverse event end date
Second adverse event ending month
Second adverse event ending year
Second adverse events grade (CTCAE v5)
Adverse event type (CTCAE Term)
Please specify
Third adverse event starting date
Third adverse event starting month
Third adverse event starting year
Third adverse event ongoing
Third adverse event end date
Third adverse event ending month
Third adverse event ending year
Third adverse events grade (CTCAE v5)
Adverse event type (CTCAE Term)
Please specify
Fourth adverse event starting date
Fourth adverse event starting month
Fourth adverse event starting year
Fourth adverse event ongoing
Fourth adverse event end date
Fourth adverse event ending month
Fourth adverse event ending year
Fourth adverse events grade (CTCAE v5)
Adverse event type (CTCAE Term)
Please specify
Fifth adverse event starting date
Fifth adverse event starting month
Fifth adverse event starting year
Fifth adverse event ongoing
Fifth adverse event end date
Fifth adverse event ending month
Fifth adverse event ending year
Fifth adverse events grade (CTCAE v5)
Patient included in a clinical trial
Date of enrolment
Surgery performed?
Surgery date
Month of surgery
Year of surgery
Tumor site, type of  surgery
Neck dissection
Node picking
Lymphography and Sentinel node
Number of lymph nodes removed
Number of positive lymph nodes
Reconstruction
Margins after surgery
LNR (Lymph node ratio)
Capsular effraction
Unknown
Unknown
Surgical complications (Clavien-Dindo Classification)
Surgery site
Chemotherapy performed?
Setting
Start date
Unknown
End date
Unknown
Number of cycles
Unknown
Drug 1
Unknown
Drug 2
Unknown
Drug 3
Unknown
Drug 4
Unknown
Drug 5
Unknown
Regimen
Plasmatic EBV DNA during/after chemotherapy
Primer type
Copy Number
Reason for end of treatment
Treatment response
Immunotherapy performed?
Setting
Start date
Unknown
End date
Unknown
Number of administrations
Unknown
Drug 1
Unknown
Drug 2
Unknown
Drug 3
Unknown
Drug 4
Unknown
Drug 5
Unknown
Reason for end of treatment
Treatment response
Target therapy performed?
Setting
Start date
Unknown
End date
Unknown
Number of cycles
Unknown
Drug 1
Unknown
Drug 2
Unknown
Drug 3
Unknown
Drug 4
Unknown
Drug 5
Unknown
Reason for end of treatment
Treatment response
Radiotherapy performed?
Intent
Site, T
Site, N
Site, M
Setting
Beam quality
Photons treatment technique
Photons start date
Photons end date
Photons total dose
Photons dose per fraction
Photons number fraction
Photons OTT
Photons 4D treatment
Photons adaptive RT
Photons IGRT  (imagine guide radiotherapy)
Electrons treatment technique
Electrons start date
Electrons end date
Electrons total dose
Electrons dose per fraction
Electrons number fraction
Electrons OTT
Electrons 4D treatment
Electrons  adaptive RT
Electrons IGRT  (imagine guide radiotherapy)
Protons treatment technique
Protons start date
Protons total dose
Protons end date
Protons dose per fraction
Protons nr fraction
Protons OTT
Protons 4D treatment
Protons adaptive RT
Protons IGRT  (imagine guide radiotherapy)
Carbons treatment technique
Carbons start date
Carbons end date
Carbons total dose
Carbons dose per fraction 
Carbons number fraction 
Carbons OTT
Carbons 4D treatment
Carbons adaptive RT
Carbons IGRT  (imagine guide radiotherapy)
Brachytherapy treatment technique
Brachytherapy start date
Brachytherapy end date
Brachytherapy total dose
Brachytherapy dose per fraction 
Brachytherapy number fraction 
Brachytherapy OTT
Brachytherapy 4D treatment
Brachytherapy adaptive RT
Brachytherapy IGRT  (imagine guide radiotherapy)
Radionuclide treatment technique
Radionuclide start date
Radionuclide end date
Radionuclide total dose
Radionuclide dose per fraction 
Radionuclide number fraction 
Radionuclide OTT
Radionuclide 4D treatment
Radionuclide adaptive RT
Radionuclide IGRT  (imagine guide radiotherapy)
<div class=rich-text-field-label><table style=border-collapse: collapse; width: auto; border=1> <tbody> <tr> <td style=vertical-align: top; text-align: center; width: 629px; colspan=9>Boron neutron capture therapy</td> </tr> <tr> <td style=width: 159px; vertical-align: top;>Treatment technique</td> <td style=width: 100px; vertical-align: top;>Start date</td> <td style=width: 100px; vertical-align: top;>End date</td> <td style=width: 70px; vertical-align: top;>Totale dose</td> <td style=width: 70px; vertical-align: top;>Dose per fraction</td> <td style=width: 70px; vertical-align: top;>Nr of fractions</td> <td style=width: 60px; vertical-align: top;>4D treatment</td> <td style=width: 70px; vertical-align: top;>Adaptive RT</td> <td style=width: 70px; vertical-align: top;>IGRT</td> </tr> <tr> <td style=width: 159px; vertical-align: top; rowspan=2>{radio_boron_tech}</td> <td style=width: 100px; vertical-align: top;>{radio_boron_from}</td> <td style=width: 100px; vertical-align: top;>{radio_boron_to}</td> <td style=width: 70px; vertical-align: top; rowspan=2>{radio_boron_totdose}</td> <td style=width: 70px; vertical-align: top; rowspan=2>{radio_boron_fractdose}</td> <td style=width: 70px; vertical-align: top; rowspan=2>{radio_boron_nrfract}</td> <td style=width: 60px; vertical-align: top; rowspan=2>{radio_boron_4d}</td> <td style=width: 70px; vertical-align: top; rowspan=2>{radio_boron_adaptive}</td> <td style=width: 70px; vertical-align: top; rowspan=2>{radio_boron_igrt}</td> </tr> <tr> <td style=width: auto; vertical-align: top; text-align: center; colspan=2>OTT (days) {radio_boron_ott}</td> </tr> </tbody> </table></div>
Boron neutron capture therapy treatment technique
Boron neutron capture therapy start date
Boron neutron capture therapy end date
Boron neutron capture therapy total dose
Boron neutron capture therapy dose per fraction 
Boron neutron capture therapy number fraction 
Boron neutron capture therapy OTT
Boron neutron capture therapy 4D treatment
Boron neutron capture therapy adaptive RT
Boron neutron capture therapy IGRT  (imagine guide radiotherapy)
<div class=rich-text-field-label><p></p> <table style=border-collapse: collapse; width: auto; border=1> <tbody> <tr> <td style=vertical-align: top; text-align: center; width: 629px; colspan=9>Others</td> </tr> <tr> <td style=width: 159px; vertical-align: top;>Treatment technique</td> <td style=width: 100px; vertical-align: top;>Start date</td> <td style=width: 100px; vertical-align: top;>End date</td> <td style=width: 70px; vertical-align: top;>Totale dose</td> <td style=width: 70px; vertical-align: top;>Dose per fraction</td> <td style=width: 70px; vertical-align: top;>Nr of fractions</td> <td style=width: 60px; vertical-align: top;>4D treatment</td> <td style=width: 70px; vertical-align: top;>Adaptive RT</td> <td style=width: 70px; vertical-align: top;>IGRT</td> </tr> <tr> <td style=width: 159px; vertical-align: top; rowspan=2>{radio_others_tech}</td> <td style=width: 100px; vertical-align: top;>{radio_others_from}</td> <td style=width: 100px; vertical-align: top;>{radio_others_to}</td> <td style=width: 70px; vertical-align: top; rowspan=2>{radio_others_totdose}</td> <td style=width: 70px; vertical-align: top; rowspan=2>{radio_others_fractdose}</td> <td style=width: 70px; vertical-align: top; rowspan=2>{radio_others_nrfract}</td> <td style=width: 60px; vertical-align: top; rowspan=2>{radio_others_4d}</td> <td style=width: 70px; vertical-align: top; rowspan=2>{radio_others_adaptive}</td> <td style=width: 70px; vertical-align: top; rowspan=2>{radio_others_igrt}</td> </tr> <tr> <td style=width: auto; vertical-align: top; text-align: center; colspan=2>OTT (days) {radio_others_ott}</td> </tr> </tbody> </table></div>
Others treatment technique
Others start date
Others end date
Others total dose
Others dose per fraction 
Others number fraction 
Others OTT
Others 4D treatment
Others adaptive RT
Others IGRT  (imagine guide radiotherapy)
Plasmatic EBV DNA during/after radiotherapy
Primer type
Copy Number
Reason for end of treatment
Treatment response
Other treatment performed?
<div class=rich-text-field-label><p style=margin-bottom: .0001pt; line-height: normal;></p> <table style=border-collapse: collapse; width: 100%; height: 21px; border=0> <tbody> <tr style=height: 21px;> <td style=width: auto; height: 21px; vertical-align: top;><strong>Date of other treatment</strong></td> <td style=width: 100px; vertical-align: top; text-align: left;>{other_treatment_date}<br /> <div style=text-align: center; font-size: 10px;>(DD-MM-YYYY Format)</div> </td> </tr> </tbody> </table> <p style=margin-bottom: .0001pt; line-height: normal;></p> <p style=margin-bottom: .0001pt; line-height: normal;><strong> If day of other treatment is unknown, please indicate month and year<br /><br /></strong></p> <table style=border-collapse: collapse; width: 100%; height: 21px; border=0> <tbody> <tr style=height: 21px;> <td style=width: 200px; height: 21px; vertical-align: top;>month</td> <td style=width: 150px; vertical-align: top; text-align: left;>{other_treatment_date_mm}<br /> <div style=text-align: center; font-size: 10px;>(MM Format)</div> </td> <td style=width: 200px; height: 21px; vertical-align: top; text-align: right;>year</td> <td style=width: 150px; text-align: left; vertical-align: top;>{other_treatment_date_yyyy}<br /> <div style=text-align: center; font-size: 10px;>(YYYY Format)</div> </td> </tr> </tbody> </table> <p></p></div>
Date
Month of other treatment
Year of other treatment
Type
Reason for end of treatment
Treatment response (based on imaging no defined criteria)
Treatment response defined/done:
Patient included in a clinical trial
<div class=rich-text-field-label><p style=margin-bottom: .0001pt; line-height: normal;></p> <table style=border-collapse: collapse; width: 100%; height: 21px; border=0> <tbody> <tr style=height: 21px;> <td style=width: auto; height: 21px; vertical-align: top;><strong>Date of enrolment</strong></td> <td style=width: 100px; vertical-align: top; text-align: left;>{oth_enrolment_date}<br /> <div style=text-align: center; font-size: 10px;>(DD-MM-YYYY Format)</div> </td> </tr> </tbody> </table> <p style=margin-bottom: .0001pt; line-height: normal;></p> <p style=margin-bottom: .0001pt; line-height: normal;><strong> If day of enrolment is unknown, please indicate month and year<br /><br /></strong></p> <table style=border-collapse: collapse; width: 100%; height: 21px; border=0> <tbody> <tr style=height: 21px;> <td style=width: 200px; height: 21px; vertical-align: top;>month</td> <td style=width: 150px; vertical-align: top; text-align: left;>{oth_enrolment_date_mm}<br /> <div style=text-align: center; font-size: 10px;>(MM Format)</div> </td> <td style=width: 200px; height: 21px; vertical-align: top; text-align: right;>year</td> <td style=width: 150px; text-align: left; vertical-align: top;>{oth_enrolment_date_yyyy}<br /> <div style=text-align: center; font-size: 10px;>(YYYY Format)</div> </td> </tr> </tbody> </table> <p></p></div>
Date of enrolment
Month of enrolment
Year of enrolment
Imaging after treatment available at the hospital?
US
CT
MRI
PET
Optical digital methods (e.g. narrow-band imaging)
CT/PET
Is tumour material available at the hospital level?
FFPE
Frozen tissue
Plasma
Blood
Faeces
Urine
Saliva
Others
Others (please specify)
Treatment response
Treatment response defined/done:













































































































































































































































































































































Patient's EUPID Pseudonym

Patient's date of birth
Patient's Sex 
Country where the patient is registered
Center where the patient is registered
Patient's country of birth
Patient's town of birth
Country where patient lives most of his/her time
Any migration for health reasons


Definition whether consent for patient's registration was obtained
Definition whether consent to be contacted was obtained
Definition whether consent for reuse of patient's data for research was obtained
Did the patient suffer from any malignancy before?
Description of any previous malignancy
Date of diagnosis of previous malignancy

 Chemotherapy/radiotherapy/surgery/immunotherapy/biological agents/other/unknown

Presence or absence of any disease which might be related or not to current malignancy
Description of relevant concomitant disease
Presence or absence of any syndrome
Definition of the syndrome affecting the patient
Report if any specific genetic abnormallitis have been detected in the patient


Presence or abscence of relevant disease in the patient's first degree relatives
Definition of disease affecting the patient's first degree relative
Age at which symptoms/signs first appeared
Definition of symptoms and signs caused by the tumor

Date in which the patient was firstly seen in a specialized centre
Age at which diagnosis was made
The case has been discussed within an official national or international VRT board for diagnosis and/or treatment
Date of referral to a Very rare Tumor board
Possible inclusion in a trial or protocol for treatment
Definition of possible trial/protocol in which the patient was enrolled
Final diagnosis 
Date of diagnostic surgery; if no surgery performed please record the start of treatment date
no/yes,local diagnosis confirmed/yes,local diagnosis changed
Patient’s biological sample available




Molecular abnormalities detected in the tumor tissue


Site of the primary tumor
Side of the primary tumor
Maximum diameter of the tumor
Local invasiveness according to clinical and radiology assessment (TNM system)
Regional lymphnodes involvement according to clinical, radiology or pathology evidence (TNM system)
Presence of distant lesions (TNM system)
Definition of the site of metastases
Definition of the site of metastases
Definition of the number of metastases for every site

Please specifiy if this treatment has been given as first line treatment or after relapse or progression
Report if a biopsy has been perfomed before starting any medical treatment
Date of biopsy
Result of resection (before any medical treatment, including primary re-excision) if perfomed 
Date of resection 
Surgery perfomed after initial treatment (chemo, radio,other)
Date of delayed surgery
A form to be completed if additional surgery has been perfomed
Report if a further biopsy or resection have been perfomed
Date of delayed surgery
Report if a biopsy has been perfomed before starting any medical treatment
Date of biopsy
Result of resection (before any medical treatment) if perfomed 
Date of resection 
Surgery perfomed after initial treatment (chemo, radio,other)
Date of delayed surgery
Report if a biopsy has been perfomed before starting any medical treatment
Date of biopsy
Result of resection (before any medical treatment) if perfomed 
Date of resection 
Surgery perfomed after initial treatment (chemo, radio,other)
Date of delayed surgery

Presence or absence of any surgical complication 
Grade according Clavien Dindo classification
Definition of complication

First day of chemoterapy
Last day of chemoterapy


Please record the best response to chemotherapy obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable)
Please report Grade IV toxicity (excluding hematologic toxicity)


First day of radiotherapy
Last day of radiotherapy
Definition fo the type of radiotherapy administered

Report the total dose of radiotherapy  in Gy (including any boost)
Report the radiotherapy target
Describe any adverse effect related  to radiotherapy if any


Immunotherapy, target agents, metabolic therapy, other/unknown

Date when therapy was started
Date when therapy was ended
Please record the best response obtained at any point of treatment but before radiotherapy or surgery  (if radiotherapy is given concomitantly the response is not evaluable)
Date of the last chemotherapy cycle or the last surgical procedure or the last day of radiotherapy or the last day of any other treatment whichever come last.

Date of the last contact with the patient including visit and telephone call
Patient alive or dead
If the patient is alive reports the status of the disease


if the patient is dead specfiy the cause of death

Date when the patient died
If any event has occurred 
Definition of the type of event that has occured
Date when the event occurred

Event treated or not


Patient's ID
Identifier fore-REC
Patients Pseudonym
Consent to add patients details to the Core Registry
Patients date of birth
Assigned sex at birth
Current gender
Country of birth
Country of residence at first presentation of condition
Current follow up
Patient's year of death
Main cause of death
Country where the notifying centre is based
City where the notifying centre is based
Details of the notifying centre
Month and year of first contact with notifying centre
Senior endocrine clinician responsible for case for clinical care and data governance
One of eight MTGs of Endo-ERN
Approximate date at which symptoms and signs first appeared
Conditions covered within each Condition Group
Orphacode for condition entered in 6.3
Select all modalities that were used to reach the diagnosis
Date when diagnosis is suspected
Patient's permission to be contacted for research purpose through local clinician (5.5)
Patient's permission for the data to be shared internationally for research purpose
Patient's permission to be contacted to complete a Pateint Reported Outcome by local clinician (5.5)
Patient is provided with access to a read-only version of their record
Information will be provided when obtaining consent on how to create an account and access data on Core Registry
Involvement in detailed disease registries
Name

Patient has a sample stored in a biobank for research to be used subject to further ethics approval
Details of biobank

Generic Patient Reported Outcomes using Euroqol EQ-5D 
Questionnaires specific to diagnosis
For audit trail
For audit trail
Serum free T4 for local reference range
Serum Total T3 for local reference range
Serum TSH for local reference range
Serum Tg (on thyroxin treatment) either TSH-suppressed < 0,2 ng/ml or TSH-stimulated < 1 ng/ml
Serum Ct < 150 pg/ml
Resting heart rate for age
Height SDS to one decimal point
Height in cm
Weight SDS to one decimal point
Weight in kg
Based on body weight and height 
International Standard Classification of Education (ISCED) 2011
Requiring extra help at school with learning
It takes your child longer than other people to get his or her school work done in past 4 weeks - severity
Using biochemical and/or imaging tests according (international) guidelines

Sporadic phaeochromocytoma/secreting paraganglioma
Sporadic phaeochromocytoma
ACTH-independent Cushing syndrome due to cortisol-producing adrenal tumour
ACTH-independent Cushing syndrome
Adrenocortical carcinoma
Adrenocortical carcinoma with pure aldosterone hypersecretion
Primary adrenal insufficiency
Chronic adrenocorticoid insufficiency
Acquired chronic primary adrenal insufficiency
Autoimmune polyendocrinopathy type 1
Autoimmune polyendocrinopathy type 2
Autoimmune polyendocrinopathy type 4
Familial glucocorticoid deficiency
Familial steroid-resistant nephrotic syndrome with adrenal insufficiency
Genetic chronic primary adrenal insufficiency
Kearns-Sayre syndrome
Primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency
Smith-Lemli-Opitz syndrome
Triple A syndrome
X-linked adrenoleukodystrophy
Neonatal adrenoleukodystrophy
Congenital Adrenal Hyperplasia
21-hydroxylase def (CYP21A)
11b-hydroxylase def (CYP11B1)
3b-HSD def (HSD3B2)
CYP17 def (P450CYP17)
P450 oxidoreductase def (POR)
P450 scc def (CYP11A1)
StAR def
Familial hyperaldosteronism
Familial hyperaldosteronism type I
Familial hyperaldosteronism type II
Familial hyperaldosteronism type III
Hypoparathyroidism
Autoimmune hypoparathyroidism
Secondary hypoparathyroidism due to impaired parathormone secretion
Dahlberg-Borer-Newcomer syndrome
Syndrome with hypoparathyroidism
Familial isolated hypoparathyroidism due to impaired PTH secretion
Genetic hypoparathyroidism
Hypoparathyroidism-sensorineural deafness-renal disease syndrome
Familial isolated hypoparathyroidism
Familial isolated hypoparathyroidism due to agenesis of parathyroid gland
Sanjad-Sakati syndrome
Autoimmune polyendocrinopathy type 1
Pseudohypoparathyroidism
Pseudopseudohypoparathyroidism
Pseudohypoparathyroidism type 1A
Pseudohypoparathyroidism type 1B
Pseudohypoparathyroidism type 1C
Pseudohypoparathyroidism type 2
Pseudohypoparathyroidism with Albright hereditary osteodystrophy
Pseudohypoparathyroidism without Albright hereditary osteodystrophy
Hypocalcaemic vitamin D-dependent rickets
Hypocalcaemic vitamin D-resistant rickets
Hyperparathyroidism
Familial isolated hyperparathyroidism
Familial primary hyperparathyroidism
Genetic hyperparathyroidism
Hyperparathyroidism-jaw tumour syndrome
Neonatal severe primary hyperparathyroidism
Nephropathy-deafness-hyperparathyroidism syndrome
Parathyroid carcinoma
Familial parathyroid adenoma
Primary parathyroid hyperplasia
Autosomal recessive infantile hypercalcaemia
Blue diaper syndrome
Familial hypocalciuric hypercalcaemia
Familial hypocalciuric hypercalcaemia type 1
Familial hypocalciuric hypercalcaemia type 2
Familial hypocalciuric hypercalcaemia type 3
Hypophosphataemic rickets
Autosomal dominant hypophosphataemic rickets
Autosomal recessive hypophosphataemic rickets
Dominant hypophosphataemia with nephrolithiasis or osteoporosis
Hereditary hypophosphataemic rickets with hypercalciuria
X-linked hypophosphataemia
Dent disease
Familial hyperphosphataemic tumoural calcinosis/Hyperphosphataemic hyperostosis syndrome
Oncogenic osteomalacia
Diabetes mellitus
Diabetes mellitus type 1
Diabetes mellitus type 2
Other diabetes mellitus
Genetic diabetes mellitus
MODY
HNF4A-MODY1
GCK-MODY2
HNF1A-MODY3
HNF1B-MODY5
Other genetically specified MODY
Neonatal diabetes
KCNJ11
ABCC8
INS
6q24
GATA6
GATA4
EIF2AK3
FOXP3
Other genetically specified neonatal diabetes
Neonatal diabetes of unknown etiology
Genetic defects in insulin action
INSR deficiency
Congenital-generalized lipodystrophy
Familial partial lipodystrophy Type 1
Familial partial lipodystrophy Type 2
PIK3R1 (Short Syndrome)
Other specified genetic defects in insulin action
Cystic fibrosis-related diabetes
Autoimmune polyglandular syndrome I
Autoimmune polyglandular syndrome II
CTLA-4
LRBA
STAT3
Other rare forms of immune mediated diabetes 
Familial hyperinsulinism
Diazoxide-sensitive diffuse hyperinsulinism
Diazoxide-resistant diffuse hyperinsulinism
Exercise-induced hyperinsulinism
Hyperinsulinism due to HNF4A deficiency
Hyperinsulinism due to INSR deficiency
Hyperinsulinism due to UCP2 deficiency
Autosomal dominant hyperinsulinism due to SUR1 deficiency
Autosomal dominant hyperinsulinism due to Kir6.2 deficiency
Diazoxide-resistant hyperinsulinism
Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency
Diazoxide-resistant focal hyperinsulinism due to Kir6.2 deficiency
Hyperinsulinism due to HNF1A deficiency
Hyperinsulinism-hyperammonaemia syndrome
Congenital isolated hyperinsulinism
Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency
Diazoxide-resistant focal hyperinsulinism
Hyperinsulinism due to glucokinase deficiency
Autosomal recessive hyperinsulinism due to SUR1 deficiency
Autosomal recessive hyperinsulinism due to Kir6.2 deficiency
ABCC8
KCNJ11
HNF4A
Beckwith-Wiedemann syndrome
Sotos syndrome
Kabuki syndrome
Other syndromic form of CH
Insulin-resistance syndrome
Acanthosis nigricans-insulin resistance-muscle cramps-acral enlargement syndrome
Growth delay due to insulin-like growth factor I resistance
Insulin-resistance syndrome type A
Insulin-resistance syndrome type B
Microcephalic primordial dwarfism-insulin resistance syndrome
Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency
Short fifth metacarpals-insulin resistance syndrome
Multiple endocrine neoplasia
Multiple endocrine neoplasia type 1
Multiple endocrine neoplasia type 2
Multiple endocrine neoplasia type 2A
Multiple endocrine neoplasia type 2B
Multiple endocrine neoplasia type 4
Carney Complex
Carney complex-trismus-pseudocamptodactyly syndrome
Hereditary pheochromocytoma-paraganglioma
Von Hippel-Lindau disease
Silver-Russell Syndrome
Silver-Russell syndrome due to 11p15 microduplication
Silver-Russell syndrome due to 7p11.2p13 microduplication
Silver-Russell syndrome due to a point mutation
Silver-Russell syndrome due to an imprinting defect of 11p15
Silver-Russell syndrome due to maternal uniparental disomy of chromosome 11
Silver-Russell syndrome due to maternal uniparental disomy of chromosome 7
Beckwith-Wiedemann Syndrome
Beckwith-Wiedemann syndrome due to 11p15 microdeletion
Beckwith-Wiedemann syndrome due to 11p15 microduplication
Beckwith-Wiedemann syndrome due to 11p15 translocation/inversion
Beckwith-Wiedemann syndrome due to CDKN1C mutation
Beckwith-Wiedemann syndrome due to NSD1 mutation
Beckwith-Wiedemann syndrome due to imprinting defect of 11p15
Beckwith-Wiedemann syndrome due to paternal uniparental disomy of chromosome 11
Prader-Willi Syndrome
6q16 microdeletion syndrome
Prader-Willi syndrome due to imprinting mutation
Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15
Prader-Willi syndrome due to paternal 15q11q13 deletion
Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1
Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2
Prader-Willi syndrome due to translocation
Prader-Willi-like syndrome
Prader-Willi-like syndrome due to a MAGEL2 or point mutation
Prader-Willi-like syndrome due to a point mutation
Urban-Rogers-Meyer syndrome
Noonan Syndrome
Neurofibromatosis-Noonan syndrome
Noonan syndrome and Noonan-related syndrome
Noonan syndrome with multiple lentigines
Noonan syndrome-like disorder with juvenile myelomonocytic leukemia
Noonan syndrome-like disorder with loose anagen hair
Short rib-polydactyly syndrome, Saldino-Noonan type
Laron syndrome
Overgrowth Syndrome
15q overgrowth syndrome
CLOVES syndrome
Chromosomal disease with overgrowth
Global developmental delay-lung cysts-overgrowth-Wilms tumour syndrome
Malan overgrowth syndrome
Megalencephaly-severe kyphoscoliosis-overgrowth syndrome
Non syndromic limb overgrowth
Overgrowth or tall stature syndrome with skeletal involvement
Overgrowth syndrome with 2q37 translocation
Overgrowth-macrocephaly-facial dysmorphism syndrome
Overgrowth-metaphyseal undermodeling-spondylar dysplasia syndrome
Overgrowth/obesity syndrome
PIK3CA-related overgrowth syndrome
Segmental progressive overgrowth syndrome with fibroadipose hyperplasia
Skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome
Tall stature-intellectual disability-facial dysmorphism syndrome
Weaver syndrome
Non-Syndromic Genetic Obesity - Congenital Leptin Resistance
Leptin receptor gene deficiency
Melanocortin 4 receptor deficiency
Prohormone convertase I deficiency
Pro-opiomelanocortin deficiency
Non-Syndromic Genetic Obesity - Other
CEP19 deficiency
Obesity due to congenital leptin deficiency
SIM1 deficiency
Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency
Syndromic Genetic Obesity – Prader-Willi Syndrome
6q16 microdeletion syndrome
Prader-Willi syndrome due to imprinting mutation
Prader-Willi syndrome due to maternal uniparental disomy of chromosome 15
Prader-Willi syndrome due to paternal 15q11q13 deletion
Prader-Willi syndrome due to paternal deletion of 15q11q13 type 1
Prader-Willi syndrome due to paternal deletion of 15q11q13 type 2
Prader-Willi syndrome due to translocation
Syndromic Genetic Obesity – PWS like Syndrome
Prader-Willi-like syndrome due to a MAGEL2 or point mutation
Prader-Willi-like syndrome due to a point mutation
Urban-Rogers-Meyer syndrome
SIM1-related Prader-Willi-like syndrome
Syndromic Genetic Obesity – PHP with AHO
Pseudohypoparathyroidism type 1A
Pseudohypoparathyroidism type 1C
Pseudopseudohypoparathyroidism
Syndromic Genetic Obesity – Rubenstein Taybi Syndrome
Rubinstein-Taybi syndrome due to 16p13.3 microdeletion
Rubinstein-Taybi syndrome due to CREBBP mutations
Rubinstein-Taybi syndrome due to EP300 haploinsufficiency
Syndromic Genetic Obesity – Temple Syndrome
Temple syndrome due to maternal uniparental disomy of chromosome 14
Temple syndrome due to paternal 14q32.2 hypomethylation
Temple syndrome due to paternal 14q32.2 microdeletion
Syndromic Genetic Obesity - Other
Alström syndrome
Bardet-Biedl syndrome
Borjeson-Forssman-Lehmann syndrome
Carpenter syndrome
Coffin-Lowry syndrome
Cognitive impairment-coarse facies-heart defects-obesity-pulmonary involvement-short stature-skeletal dysplasia syndrome
Cohen syndrome
Colobomatous microphthalmia-obesity-hypogenitalism-intellectual disability syndrome
Distal 16p11.2 microdeletion syndrome
Fragile X syndrome
Hydrocephalus-obesity-hypogonadism syndrome
Intellectual disability-obesity-brain malformations-facial dysmorphism syndrome
Intellectual disability-obesity-prognathism-eye and skin anomalies syndrome
Intellectual disability-seizures-macrocephaly-obesity syndrome
MEHMO syndrome
Microcephalic osteodysplastic primordial dwarfism type II
MOMO syndrome
MORM syndrome
ROHHAD syndrome
Short stature-brachydactyly-obesity-global developmental delay syndrome
Smith-Magenis syndrome
Spastic paraplegia-intellectual disability-nystagmus-obesity syndrome
Symptomatic form of Coffin-Lowry syndrome in female carriers
WAGR syndrome
Wilson-Turner syndrome
Xq21 microdeletion syndrome
Pituitary adenoma
Cushing disease
Familial isolated pituitary adenoma
Functioning gonadotropic adenoma
Functioning pituitary adenoma
Mixed functioning pituitary adenoma
Non-functioning pituitary adenoma
Null pituitary adenoma
Prolactinoma
Silent pituitary adenoma
Somatomammotropinoma
TSH-secreting pituitary adenoma
Non-acquired combined pituitary hormone deficiency
Combined pituitary hormone deficiencies, genetic forms
Disease associated with non-acquired combined pituitary hormone deficiency
Non-acquired pituitary hormone deficiency
Congenital hypogonadotropic hypogonadism
Congenital isolated ACTH deficiency
Acquired pituitary hormone deficiency
Pituitary hormone deficiency from meningeal origin
Panhypopituitarism
RHYNS syndrome
Septo-optic dysplasia spectrum
Sex chromosome disorder of sex development
45,X
45,X/46,XY
46,XX/46,XY
47,XXY
48,XXXY
48,XXYY
49,XXXXY
Other
Cloacal anomaly and other
Bladder Exstrophy
Congenital Adrenal Hyperplasia
21-hydroxylase def (CYP21A)
11b-hydroxylase def (CYP11B1)
3b-HSD def (HSD3B2)
CYP17 def (P450CYP17)
P450 oxidoreductase def (POR)
P450 scc def (CYP11A1)
StAR def
Disorder of androgen action
PAIS
CAIS
Disorder of Androgen Excess
21-hydroxylase def (CYP21A)
11b-hydroxylase def (CYP11B1)
Aromatase def (CYP19A1)
P450 oxidoreductase def (POR)
Maternal Androgens
Disorder of androgen synthesis
StAR def
P450 scc def (CYP11A1)
3b-HSD def (HSD3B2)
CYP17 def (P450CYP17)
Combined 17a-hydroxylase/17,20 lyase deficiency
Isolated 17,20 lyase deficiency
17b-HSD def (HSD17B3)
5a-reductase def (SRD5A2)
P450 oxidoreductase def (POR)
Disorder of gonadal development
Complete gonadal dysgenesis
Partial gonadal dysgenesis
Gonadal regression
Ovotesticular DSD
Testicular DSD
Leydig Cell Hypoplasia
LH deficiency
Non-specific
Isolated hypospadias
Isolated bilateral cryptorchidism
Isolated micropenis
Complex genital anomalies
EMS < 5
EMS 5-8
EMS >/= 9
Persistent mullerian duct syndrome
AMH low
AMH normal
AMH not known
Smith Lemli Opitz Syndrome
Other
Cloacal anomaly and other
Bladder Exstrophy
Congenital Adrenal Hyperplasia
21-hydroxylase def (CYP21A)
11b-hydroxylase def (CYP11B1)
3b-HSD def (HSD3B2)
CYP17 def (P450CYP17)
P450 oxidoreductase def (POR)
P450 scc def (CYP11A1)
StAR def
Defects of mullerian development
MURCS
MRKS
Disorder of Androgen Excess
21-hydroxylase def (CYP21A)
11b-hydroxylase def (CYP11B1)
Aromatase def (CYP19A1)
P450 oxidoreductase def (POR)
Maternal Androgens
Disorder of gonadal development
Complete gonadal dysgenesis
Partial gonadal dysgenesis
Gonadal regression
Ovotesticular DSD
Testicular DSD
Smith Lemli Opitz Syndrome
Other
Kallmann Syndrome
Normosmic congenital hypogonadotropic hypogonadism
Transgender, male to female
Transgender, female to male
MCT8 deficiency
Resistance to thyroid hormone alpha
Resistance to thyroid hormone beta
SBP2 deficiency
Transient congenital hypothyroidism
Permanent congenital hypothyroidism
Familial hyperthyroidism due to mutations in TSH receptor
Familial gestational hyperthyroidism
Paediatric-onset Graves disease
Papillary thyroid carcinoma
Follicular thyroid carcinoma
Medullary thyroid carcinoma
Primary bone dysplasia with disorganized development of skeletal components
McCune-Albright syndrome 
Fibrous dysplasia of bone (incl MAS)
Polyostotic fibrous dysplasia 
Monostotic fibrous dysplasia 
Mazabraud syndrome 
Maffucci syndrome 
Multiple osteochondroma
Multiple metaphyseal dysplasia
Pseudoachondroplasia 
Epimetaphyseal skeletal dysplasia 
Metaphyseal anadysplasia
Metaphyseal acroscyphodysplasia
Metaphyseal chondrodysplasia, Schmid type 
Ulna metaphyseal dysplasia syndrome 
Metaphyseal chondrodysplasia, Spahr type
Metaphyseal dysostosis-intellectual disability-conductive deafness syndrome
Metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome 
Cartilage-hair hypoplasia 
Shwachman-Diamond syndrome 
Metaphyseal chondrodysplasia, Jansen type 
Metaphyseal chondrodysplasia-retinitis pigmentosa syndrome 
Metaphyseal chondrodysplasia, Kaitila type 
Spondylodysplastic dysplasia 
Mesomelic and rhizo-mesomelic dysplasia
Léri-Weill dyschondrosteosis 
Cleidorhizomelic syndrome 
Dyschondrosteosis-nephritis syndrome 
Mesomelic dysplasia, Kantaputra type 
Fibrochondrogenesis 
Upper limb mesomelic dysplasia 
Mesomelic dwarfism-cleft palate-camptodactyly syndrome 
Langer mesomelic dysplasia 
Mesomelic dwarfism, Nievergelt type 
Mesomelic dwarfism, Reinhardt-Pfeiffer type 
Omodysplasia 
Rhizomelic syndrome, Urbach type 
Rhizomelic dysplasia, Patterson-Lowry type 
Madelung deformity 
Atelosteogenesis type II 
Mesomelic dysplasia, Savarirayan type 
Robinow syndrome 
SHOX-related short stature 
Short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome 
Colobomatous microphthalmia-rhizomelic dysplasia syndrome 
Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome 
Primary bone dysplasia with increased bone density
Juvenile Paget disease 
Camurati-Engelmann disease 
Craniodiaphyseal dysplasia 
Craniometaphyseal dysplasia 
Osteopetrosis 
High bone mass osteogenesis imperfecta 
Melorheostosiswithosteopoikilosis
Primary bone dysplasia with decreased bone density
Congenital osteogenesis imperfecta-microcephaly-cataracts syndrome 
Osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome 
Osteogenesis imperfecta 
OI type 1
OI type 2
OI type 3
OI type 4
OI type 5
Idiopathic juvenile osteoporosis
Ehlers-Danlos/osteogenesis imperfecta syndrome 
X-linked osteoporosis with fractures 
Primary bone dysplasia with defective bone mineralization
Hypophosphatasia
Perinatal lethal hypophosphatasia 
Prenatal benign hypophosphatasia 
Infantile hypophosphatasia 
Childhood-onset hypophosphatasia 
Adult hypophosphatasia 
Odontohypophosphatasia 
Primary bone dysplasia with micromelia
Achondroplasia 
Hypochondroplasia
Dysostosis 
Primary bone dysplasia with progressive ossification of the skin, muscle and tendons 
 Fibrodysplasia ossificans progressiva (FOP)
 Progressive osseous heteroplasia (POH)








If 1,2,3
If 1
if 2
if 3



if gen_diagnosis=yes|no
If gen_diagnosis != result pending
if gen_diagnosis=yes

From Wiki: the degree to which both copies of a chromosome or gene have the same genetic sequence.

If no gentetic specifications are given in diagnosis



